{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:16:28Z","timestamp":1762917388463,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":4252,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s13311-011-0088-3","type":"journal-article","created":{"date-parts":[[2011,12,3]],"date-time":"2011-12-03T10:15:58Z","timestamp":1322907358000},"page":"176-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Lamotrigine XR Conversion to Monotherapy: First Study Using a Historical Control Group"],"prefix":"10.1016","volume":"9","author":[{"given":"Jacqueline A.","family":"French","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy R.","family":"Temkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassel F.","family":"Shneker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne E.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul T.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Messenheimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-011-0088-3_bib1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2165\/00023210-200822110-00003","article-title":"Designing clinical trials to assess antiepileptic drugs as monotherapy: difficulties and solutions","volume":"22","author":"Perucca","year":"2008","journal-title":"CNS Drugs"},{"issue":"24 suppl 3","key":"10.1007\/s13311-011-0088-3_bib2","first-page":"S23","article-title":"Monotherapy clinical trial design","volume":"69","author":"Sachdeo","year":"2007","journal-title":"Neurology"},{"issue":"suppl 4","key":"10.1007\/s13311-011-0088-3_bib3","first-page":"S26","article-title":"Limitations of monotherapy trials in epilepsy","volume":"60","author":"Gilliam","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-011-0088-3_bib4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-133-6-200009190-00014","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues","volume":"133","author":"Temple","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1007\/s13311-011-0088-3_bib5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1528-1157.1991.tb04715.x","article-title":"Clinical trials of investigational antiepileptic drugs: monotherapy designs","volume":"32","author":"Pledger","year":"1991","journal-title":"Epilepsy"},{"key":"10.1007\/s13311-011-0088-3_bib6","unstructured":"Declaration of Helsinki. Tokyo: World Medical Association, 2004, October 9."},{"key":"10.1007\/s13311-011-0088-3_bib7","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1528-1167.2010.02650.x","article-title":"Historical control monotherapy design in the treatment of epilepsy","volume":"51","author":"French","year":"2010","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-011-0088-3_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.eplepsyres.2005.09.028","article-title":"Historical data in the design and interpretation of trials with newly diagnosed patients","volume":"68","author":"Baulac","year":"2006","journal-title":"Epilepsy Res"},{"issue":"suppl 4","key":"10.1007\/s13311-011-0088-3_bib9","first-page":"S13","article-title":"Conversion to monotherapy: clinical trials in patients with refractory partial seizures","volume":"60","author":"Beydoun","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-011-0088-3_bib10","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1212\/WNL.51.4.1018","article-title":"An active-control trial of lamotrigine monotherapy for partial seizures","volume":"51","author":"Gilliam","year":"1998","journal-title":"Neurology"},{"key":"10.1007\/s13311-011-0088-3_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1212\/WNL.59.1.79","article-title":"Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials?","volume":"59","author":"Somerville","year":"2002","journal-title":"Neurology"},{"key":"10.1007\/s13311-011-0088-3_bib12","doi-asserted-by":"crossref","unstructured":"Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol 2011, Sept 19 [Epub ahead of print].","DOI":"10.1016\/S1474-4422(11)70193-4"},{"key":"10.1007\/s13311-011-0088-3_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1528-1167.2010.02915.x","article-title":"Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis","volume":"52","author":"Rheims","year":"2011","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-011-0088-3_bib14","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the Peripheral and Central Nervous System Drugs Advisory Committee meeting. March 10, 2011. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee\/UCM250489.pdf. Accessed May 5, 2011."},{"key":"10.1007\/s13311-011-0088-3_bib15","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-011-0088-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-011-0088-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923017750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923017750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-011-0088-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:10:24Z","timestamp":1761808224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923017750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1878747923017750"],"URL":"https:\/\/doi.org\/10.1007\/s13311-011-0088-3","relation":{},"ISSN":["1878-7479"],"issn-type":[{"type":"print","value":"1878-7479"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lamotrigine XR Conversion to Monotherapy: First Study Using a Historical Control Group","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-011-0088-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}